0.656
-0.16 (-20.02%)
| Previous Close | 0.820 |
| Open | 0.780 |
| Volume | 13,516,256 |
| Avg. Volume (3M) | 5,164,330 |
| Market Cap | 185,906,176 |
| Price / Sales | 2.51 |
| Price / Book | 7.09 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Profit Margin | -169.45% |
| Operating Margin (TTM) | -342.87% |
| Diluted EPS (TTM) | -0.490 |
| Quarterly Revenue Growth (YOY) | 269.80% |
| Total Debt/Equity (MRQ) | 134.24% |
| Current Ratio (MRQ) | 1.13 |
| Operating Cash Flow (TTM) | -67.14 M |
| Levered Free Cash Flow (TTM) | -38.09 M |
| Return on Assets (TTM) | -46.05% |
| Return on Equity (TTM) | -185.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Sangamo Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.88 |
|
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.13% |
| % Held by Institutions | 27.54% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (HC Wainwright & Co., 1,424.86%) | Buy |
| Median | 5.00 (662.43%) | |
| Low | 2.00 (RBC Capital, 204.97%) | Hold |
| Average | 5.67 (764.59%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 0.917 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Apr 2025 | 10.00 (1,424.86%) | Buy | 0.710 |
| 27 Jan 2025 | 10.00 (1,424.86%) | Buy | 1.13 | |
| RBC Capital | 18 Mar 2025 | 2.00 (204.97%) | Hold | 0.850 |
| Truist Securities | 23 Jan 2025 | 5.00 (662.43%) | Buy | 1.19 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |